NEW INVENTARIES BASED ON

LIFE SCIENCES





Submitted By
Reshma Rillison.R.J
Natural Science
Candidate Code : 13359016



Patent: Non-Viral Drug Delivery using
HES

The described invention uses for the first time a polysaccharide, hydroxyethyl
starch (HES), for the controlled shielding/deshielding of polyplexes. Designing
carriers for safe and efficient delivery of therapeutic genes offer great potential
for in vitro gene transfection as well as the in vivo the treatment of many difficult-
to cure diseases, such as metastatic cancer.












Invention: Adjuvant for improved
regional pain management



Drug Delivery: Effective pain management during trauma or orthopedic surgery
as well as in post-operative treatment is essential for the patients wellbeing and
a quick and successful recovery. It also plays an important role in the context of
chronic limb pain. Commonly used treatment options exhibit a number of
detrimental side effects. Available pain therapeutics such as local anesthetics
also impair motor and sensory function and therefore hinder rehabilitation.
Systemically (Within the Central Nervous System; CNS) applied opioids can
cause sedation, nausea and respiratory depression. Locally applied hydrophilic
opioid drugs (such as DAMGO or morphine) on the other hand could offer pain
relieve without interfering with other neuronal types and without the unwanted
side effects on the central nervous system. However, their use on nociceptive
nerve fibers of the pripheral nervous system is currently prevented by the fact
that they cannot pass the perineurial cell barrier around the peripheral nerve
cells. An invention from theJulius-Maximilian Universitt Wrzburg and
Leibniz Institute for Molecular Pharmacology (FMP) could now help to apply
these opioid drugs in the peripheral nervous system and reduce sideeffects.





Invention against Alzheimers disease
Researchers from the Ludwig-Maximilians-Universitt Mnchen and the
IIMCB Warsaw have identified a novel class of multifunctional drugs for
treatment of Alzheimers disease.
Alzheimers disease (AD), the most common form of dementia, is a growing
threat to our aging society. There is still no cure for AD and the available
treatments are very inadequate. Current AD drug development attempts mainly
focus on targeting two major hallmarks of the disease, beta-amyloid and tangle
pathologies. Calcium dysregulation is a proximal event in AD progression playing
a key role in synaptic failure and neuronal loss. Notably, the later irreversible
pathological events correlate best with the stages of dementia. Disrupted calcium
homeostasis is present early in AD development, long before the onset of
disease hallmarks or cognitive deficits. Long-term disruption of calcium
homeostasis has been shown to both trigger and accelerate amyloid and tangle
pathology. The recent unexceptional failure of AD drug candidates targeting
amyloid and tangle pathologies in late clinical phases has led to perspective
change in AD drug development. Therefore we examined the possibility of
restoring the altered cal ium homeostasis - particularly in intracellular calcium
stores, e.g. endoplasmic reticulum (ER) - in context of AD drug discovery.






Invention from FAU: Avoiding of graft
rejection and new therapy for
autoimmune diseases

Invention from the Friedrich-Alexander-Universitt Erlangen-Nrnberg for
Pharmaceutics & Medicine:
Dendritic cells (DC) are considered to be the organizers of the immune system.
In principle they can induce two reactions. On the one hand, they organize the
immune defense for the control and elimination of microbes and foreign
structures/cells, such as cancer cells. On the other hand, DCs prevent this very
immune-defence from attacking endogenous cells and structures. The latter is
also referred to as induction or maintenance of tolerance or briefly tolerization.
When tolerance is broken, the results are graft rejections, allergies or
autoimmune diseases with progressive tissue destruction as seen for example in
rheumatoid arthritis and multiple sclerosis. Unfortunately, hardly any therapies or
therapy regimens have been developed to date to induce tolerance. In the
presented new invention it is demonstrated that the i.v. application of Ontak
results in a profound tolerization of dendritic cells (DC).